Fluent BioSciences awarded NIH SBIR grant to commercialize low-cost million-cell transcriptome profiling kits powered by Ultima Genomics sequencing, prototype kits now shipping

FHS
April 9, 2024
4:20 am

Fluent BioSciences, a cutting-edge life sciences company leading the charge in revolutionizing single-cell analysis through simple, cost-effective, and highly scalable single-cell RNA sequencing solutions is thrilled to announce the award of an NIH Small Business Innovation Research (SBIR) Phase II grant, funded by the National Institute of General Medical Sciences (NIGMS, 2 R44 GM137648).

ACA subsidy optimism and a fiery antitrust speech

This is the online version of STAT’s email newsletter Health Care Inc, delivered to your inbox every Monday. Sign up here. Hello, and thanks for

November 18, 2024

High tumor monocyte content linked to better outcomes for esophageal cancer patients

A Ludwig Cancer Research study has discovered that the presence of relatively high numbers of immune cells known as monocytes in tumors is linked to

July 10, 2023

Opinion | Committee for Economic Development: A Mighty ‘Influencer’ in Health Policymaking

David Nash is the Founding Dean Emeritus and Dr. Raymond C. and Doris N. Grandon Professor of Health Policy at the Jefferson College of Population

July 30, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.